'SLS Bio, Responsible for Wegovy Quality Control, Suspended from Pharmaceutical Quality Testing Operations'

SLS Bio announced on June 9 that it has been suspended from business operations in the field of "pharmaceutical quality testing excluding quasi-drugs." The amount affected by the suspension is approximately 5.9 billion KRW, which accounts for about 70% of the company's sales last year.

The company explained that the reason for the suspension is that "among the ten competency evaluation items for researchers, which are part of the regulatory authority's evaluation criteria, the company failed to meet the standard for one item." Regarding future measures, the company stated, "We plan to request a competency re-evaluation from the Ministry of Food and Drug Safety," and added, "We will supplement the competency evaluation of our researchers to meet the standards required by the Ministry." The company also noted, "Depending on the re-evaluation schedule, the business suspension period is expected to last a maximum of two to three weeks."

SLS Bio is exclusively responsible for quality control of the obesity treatment drug Wegovy.

This content was produced with the assistance of AI translation services.